Skip Navigation

European Heart Journal 1995 16(Supplement K):49-54; doi:10.1093/eurheartj/16.suppl_K.49
Copyright © 1995 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Pitt, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pitt, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1995 The European Society of Cardiology

Potential role of angiotensin converting enzyme inhibitors in the treatment of atherosclerosis

B. Pitt

Department of Internal Medicine; University of Michigan Medical School Michigan, U.S.A.

Correspondence: Bertram Pitt, MD, Department of Internal Medicine, University of Michigan Medical School, Taubman Medical Center, Ann Arbor MI 42109-0366, U.S.A.

Recent clinical data from the SOLVD (Studies on Left Ventricular Dysfunction) and SAVE (Survival and Ventricular Enlargement) studies have shown a significant reduction in ischaemic events with ACE inhibition. When the results of the two SOLVD and the SAVE trials were combined, the overall risk reduction in myocardial infarction with long-term ACE inhibitor treatment was 23% (P <0.001) and the overall risk reduction for hospitalizations for unstable angina 15%. The time frame of the clinical effects suggests that ACE inhibitors may be working through an antiatherosclerotic mechanism, and genetic, epidemiological and mechanistic data suggest that the renin-angiotensin-aldasterone system may play a role in the atherosclerotic process. Genetic and epidemiological evidence has shown that an activated renin-angiotensin aldosterone system is associated with a higher incidence of myocardial infarction, and mechanistic studies have demonstrated that ACE inhibition can produce antiatherosclerotic effects in animal models. The antiatherosclerotic effects of ACE inhibitors may be mediated at one of several steps in the atherosclerotic pathway: blocking plaque formation, plaque rupture; or thrombus formation.

Key Words: Angiotensin converting enzyme inhibitors • atherosclerosis • heart failure • myocardial infarction • angina


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.